80018-06-0|Fengabine|(E)-2-((butylimino)(2-chlorophenyl)methyl)-4-chlorophenol|-范德生物科技公司

Fengabine

NMR下载 COA and HPLC MSDS下载
names：
(E)-2-((butylimino)(2-chlorophenyl)methyl)-4-chlorophenol
CAS号：
80018-06-0
MDL Number：
MF(分子式)： C17H17Cl2NO MW(分子量)： 322.229
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Fengabine
英文别名	SL-79229; SL 79229; SL79229; SL 79,229-00; SL 79-229; SL 79.229-00; Fengabine
CAS号	80018-06-0
Inchi	InChI=1S/C17H17Cl2NO/c1-2-3-10-20-17(13-6-4-5-7-15(13)19)14-11-12(18)8-9-16(14)21/h4-9,11,21H,2-3,10H2,1H3/b20-17-
InchiKey	ZGLIFVFRIOKQLE-JZJYNLBNSA-N
分子式 Formula	C17H17Cl2NO
分子量 Molecular Weight	322.229
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Fengabine(CAS:80018-06-0):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Fengabine, also known as SL-79229, is GABA receptor agonist potentially for the treatment of major depressive disorder (MDD). Its mechanism of action is unknown, but its antidepressant effects are reversed by GABAA receptor antagonists like bicuculline and it has hence been labeled as GABAergic; however, it does not actually bind to GABA receptors, nor does it inhibit GABA-T. In clinical trials, fengabine's efficacy was comparable to that of the tricyclic antidepressants, but with a more rapid onset of action and much less side effects. Notably, fengabine lacks any sedative effects.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Fairweather DB, Kerr JS, Hilton S, Hindmarch I. A placebo controlled double-blind evaluation of the pharmacodynamics of fengabine vs amitriptyline following single and multiple doses in elderly volunteers. Br J Clin Pharmacol. 1993 Mar;35(3):278-83. PubMed PMID: 8471403; PubMed Central PMCID: PMC1381575.

[2]Pitsiu M, Parker EM, Aarons L, Holt B, Rowland M. A comparison of the relative sensitivities of factor VII and prothrombin time measurements in detecting drug interactions with warfarin. Eur J Clin Pharmacol. 1992;42(6):645-9. PubMed PMID: 1623906.

[3] Aley KO, Kulkarni SK. Altered response to GABAergic agents following electro and chemo convulsions in mice. Indian J Exp Biol. 1991 Mar;29(3):241-3. PubMed PMID: 1651904.

[4] Nielsen NP, Cesana B, Zizolfi S, Ascalone V, Priore P, Morselli PL. Therapeutic effects of fengabine, a new GABAergic agent, in depressed outpatients: a double-blind study versus clomipramine. Acta Psychiatr Scand. 1990 Nov;82(5):366-71. PubMed PMID: 2281807.

[5] Sharma AC, Kulkarni SK. Evidence for GABA-BZ receptor modulation in short-term memory passive avoidance task paradigm in mice. Methods Find Exp Clin Pharmacol. 1990 Apr;12(3):175-80. PubMed PMID: 2161973.

6: Ascalone V, Dal Bo L, Deschamps N, Guinebault P. Determination of the GABAergic antidepressant drug fengabine and some of its metabolites in plasma by capillary gas chromatography with electron-capture detection. J Chromatogr. 1989 May 5;490(1):81-90. PubMed PMID: 2760159.7: Aley KO, Kulkarni SK. GABA-mediated modification of despair behavior in mice. Naunyn Schmiedebergs Arch Pharmacol. 1989 Mar;339(3):306-11. PubMed PMID: 2725709.8: Magni G, Garreau M, Orofiamma B, Palminteri R. Fengabine, a new GABAmimetic agent in the treatment of depressive disorders: an overview of six double-blind studies versus tricyclics. Neuropsychobiology. 1989;20(3):126-31. PubMed PMID: 2668780.9: Lloyd KG, Zivkovic B, Scatton B, Morselli PL, Bartholini G. The gabaergic hypothesis of depression. Prog Neuropsychopharmacol Biol Psychiatry. 1989;13(3-4):341-51. Review. PubMed PMID: 2664889.10: Aley KO, Kulkarni SK. Studies on the neuropsychopharmacological profile of fengabine (SL 79229) in mice. Methods Find Exp Clin Pharmacol. 1988 Sep;10(9):563-8. PubMed PMID: 3226222.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开